Tandem Diabetes Care (TNDM) Corporate presentation summary

Market opportunity and positioning

• Serves a large, underpenetrated global diabetes market, with less than 40% of type 1 and 5% of insulin-intensive type 2 patients in the U.S. using pumps.

• Approximately 480,000 in-warranty customers across 25 countries as of December 2024.

• Focused on both type 1 and type 2 diabetes, with products cleared for ages 2+.

• Committed to R&D investment while maintaining operating leverage and balance sheet strength.

Product portfolio and innovation

• Offers two main pump platforms: t:slim X2 and Tandem Mobi, both featuring Control-IQ+ technology.

• t:slim X2 is 38% smaller than leading competitors, integrates with three CGM sensors, and offers mobile app bolus delivery.

• Tandem Mobi is the world’s smallest durable automated insulin delivery system, with smartphone control and modular wearability.

• Sigi platform in development, aiming to combine patch pump wearability with durable pump flexibility.

• Extended wear infusion technology and tubeless features under development for enhanced customization.

Technology and digital ecosystem

• Control-IQ+ technology predicts and helps prevent glucose highs and lows, with automated correction bolus and simple setup.

• Tandem Source is a multi-sided diabetes management platform for patients, caregivers, clinicians, and admins, supporting data management, reporting, and device management.

• Integration with leading CGM sensors, including Dexcom G6/G7 and Abbott FreeStyle Libre 2/3 Plus.

• Ongoing expansion of digital tools and software updates to enhance therapy management.